SILVER SPRING
Linzess cleared for pediatric functional constipation
- Sponsor
- Ironwood Pharmaceuticals $IRWD
- Drug
- Linzess · linaclotide
- Indication
- Functional constipation
FDA approved Linzess (linaclotide) for pediatric patients aged 2+ with functional constipation.
What this means
Linzess is a capsule that helps relieve constipation by increasing fluid in the intestines and speeding up bowel movements. FDA has now approved Linzess for children aged 2 and older who have functional constipation, a condition where bowel movements are infrequent or difficult without a clear cause. This decision gives pediatricians and families a new treatment option, though parents should watch for signs of dehydration, a known risk in children taking the drug.
Drug Watch — recent news on Linzess
- IRWD: Turnaround year with robust growth, LINZESS resurgence, and advancing apraglutide toward 2029 NDA - TradingView
- Ironwood Pharmaceuticals at Wells Fargo conference: linzess rebound drives turnaround - Investing.com
- Ironwood raises LINZESS sales forecast but faces patent expiry risk by 2029-2030. - Pluang
- Ironwood Pharmaceuticals: High Dependence On Its Next Trial (NASDAQ:IRWD) - Seeking Alpha
- Ironwood Pharmaceuticals (IRWD) Stock Faces A Sentiment Check After Raised Guidance - webull.com
Sponsor Watch — recent news on Ironwood Pharmaceuticals
- AbbVie's Migraine Franchise Scored a Big Win. Is This Dividend King a No-Brainer Buy Right Now?
- AbbVie (ABBV) Unveiled New VRAYLAR Data In Real World And Pediatric Care
- AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
- AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
- What Would It Take For Eli Lilly Stock To Keep Climbing?